September 18, 2020 – Medtronic plc (Dublin, Ireland) announced new data from the WRAP-IT study, showing the TYRX™ Absorbable Antibacterial Envelope (TYRX Envelope) is cost effective for patients at increased risk of infections who receive cardiac implantable electronic devices (CIEDs).
The analysis, newly published in Circulation: Arrhythmia and Electrophysiology, demonstrates the envelope’s cost-effectiveness compared to standard-of-care infection prevention strategies in the U.S. healthcare system, Medtronic said.
This pre-specified analysis of the global WRAP-IT Trial (Worldwide Randomized Antibiotic Envelope Infection Trial) compared costs and patient outcomes between patients who received the TYRX Envelope and patients who received standard-of-care.
The TYRX Envelope is cost-effective in the WRAP-IT patient population, with its incremental cost effectiveness ratio well below the upper willingness to pay threshold of $150,000, the recommended threshold of the American College of Cardiology/American Heart Association practice guidelines on cost/value methodology.